▲ +83.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Eton Pharmaceuticals in the last 3 months. The average price target is $12.50, with a high forecast of $14.00 and a low forecast of $11.00. The average price target represents a 83.02% upside from the last price of $6.83.
The current consensus among 2 investment analysts is to buy stock in Eton Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.